key: cord-0814695-nkvz4574
authors: Loffredo, Madeline; Lucero, Hector; Chen, Da-Yuan; O’Connell, Aoife; Bergqvist, Simon; Munawar, Ahmad; Bandara, Asanga; De Graef, Steff; Weeks, Stephen D.; Douam, Florian; Saeed, Mohsan; Munawar, Ali H.
title: The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication
date: 2021-03-08
journal: Sci Rep
DOI: 10.1038/s41598-021-84782-w
sha: 24ae7cc04feb06ec86a26d307bf6502c95aa048c
doc_id: 814695
cord_uid: nkvz4574

The lack of coronavirus-specific antiviral drugs has instigated multiple drug repurposing studies to redirect previously approved medicines for the treatment of SARS-CoV-2, the coronavirus behind the ongoing COVID-19 pandemic. A recent, large-scale, retrospective clinical study showed that famotidine, when administered at a high dose to hospitalized COVID-19 patients, reduced the rates of intubation and mortality. A separate, patient-reported study associated famotidine use with improvements in mild to moderate symptoms such as cough and shortness of breath. While a prospective, multi-center clinical study is ongoing, two parallel in silico studies have proposed one of the two SARS-CoV-2 proteases, 3CL(pro) or PL(pro), as potential molecular targets of famotidine activity; however, this remains to be experimentally validated. In this report, we systematically analyzed the effect of famotidine on viral proteases and virus replication. Leveraging a series of biophysical and enzymatic assays, we show that famotidine neither binds with nor inhibits the functions of 3CL(pro) and PL(pro). Similarly, no direct antiviral activity of famotidine was observed at concentrations of up to 200 µM, when tested against SARS-CoV-2 in two different cell lines, including a human cell line originating from lungs, a primary target of COVID-19. These results rule out famotidine as a direct-acting inhibitor of SARS-CoV-2 replication and warrant further investigation of its molecular mechanism of action in the context of COVID-19.

www.nature.com/scientificreports/ act on the protease 8 . Other computational reports have predicted famotidine as an inhibitor of the Papain-like protease (PL pro ), a second SARS-CoV-2 protease 9 . Together, these studies have raised the prospect of a direct antiviral effect of famotidine on SARS-CoV-2 replication. While both proteins are attractive targets for SARS-CoV-2 drug development [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , there are at present no clinical-stage or approved drugs targeting either protein.

The possibility of famotidine, an approved drug, acting on SARS-CoV-2 proteases is of significant clinical interest. In this in-vitro study, we performed an array of biochemical, biophysical, and antiviral experiments to test if famotidine is an effector of SARS-CoV-2 proteases and whether it inhibits virus replication in cultured cells.

tein is critical to the generation of a functional virus replication complex 11, 18, 20 . To carry out this essential proteolytic function, the SARS-CoV-2 genome encodes two cysteine proteases, called PL pro and 3CL pro18 . Due to their critical roles in viral polyprotein processing and virus proliferation, both proteases are considered attractive targets for drug discovery 10, 11, [13] [14] [15] [16] [17] 21 . Since in silico docking studies have predicted these proteases as putative molecular targets of famotidine 6, 8, 9 , we methodically investigated the effect of famotidine on the catalytic functions of each protease. First, we developed an in-vitro activity assay of PL pro . PL pro is a protease domain found within the large multidomain nsp3 protein encoded by SARS-CoV-2. While many coronaviruses encode two papain-like proteases, SARS-CoV, MERS-CoV and SARS-CoV-2 possess only one PL pro , which processes the amino-terminal end of the viral polyprotein liberating nsp1, nsp2 and nsp3 19, 21 . Additionally, PL pro deubiquitinates host cell proteins by cleaving the consensus motif of LXGG 18, 19 and is known to efficiently hydrolyze both diubiquitin and synthetic peptide substrates 19 . We leveraged the deubiquitinating property of PL pro to set up a functional activity assay using ubiquitin-AMC, a fluorogenic substrate cleavable by PL pro . Upon incubation with PL pro , the ubiquitin is recognized and cleaved at the C-terminus to liberate the AMC (amido-4-methylcoumarin) fluorophore which results in increased fluorescence that is read using excitation and emission wavelengths of 355/460 nm. We assessed the ability of famotidine to inhibit the proteolytic activity of PL pro at a broad range of drug concentrations vis-àvis compound 6, a previously reported inhibitor of PL pro activity 21 . Experimental conditions including protein and substrate concentrations, buffer composition, and assay kinetics were optimized using compound 6. While compound 6 inhibited PL pro activity with the expected low single-digit μM IC 50 values, famotidine showed no reduction in PL pro activity in the titrated range of 0.01-200 μM (Fig. 1a) .

We next tested whether famotidine can inhibit the enzymatic activity of 3CL pro , the second protease encoded by the SARS-CoV-2 genome. This protein, also referred to as the main protease (M pro ) or nsp5, cleaves the viral polyprotein at 11 unique sites 11 . This proteolytic activity generates multiple individual functional proteins required for the assembly of the SARS-CoV-2 replication/transcription complex, which drives viral genome replication 20 . Owing to its central role in the coronavirus life cycle, 3CL pro has received significant attention as a drug target resulting in the discovery of several potent inhibitors 10, 14, 15, 17 . Native 3CL pro exists as a homodimer and requires dimerization for its proteolytic activity 11 . The catalytic mechanism of 3CL pro activity is typical of cysteine proteases, where the Cys-His catalytic dyad drives site-specific cleavage of substrates. We evaluated the enzymatic activity of 3CL pro using a FRET-peptide substrate that quenched fluorescence in its intact form, however, cleavage of the peptide substrate by 3CL pro produced fluorescence that could be measured at the excitation/ emission wavelengths of 490/535 nm. The inclusion of ML188, a previously reported 3CL pro inhibitor served as a control, also aiding assay setup and optimization. Results of the FRET assay for various ML188 and famotidine concentrations are shown in Fig. 1b . Both compounds were tested between a range of 0.01-200 μM. While ML188 produced a dose-dependent inhibition of 3CL pro activity with an expected IC 50 of 2.4 μM, famotidine did not inhibit 3CL pro activity. Effects of famotidine on PL pro and 3CL pro protease activity. In-vitro inhibition assays (IC 50 ) of PL pro (a) and 3CL pro (b) activity show that famotidine had no effect on either of the two SARS-CoV-2 proteases. IC 50 values represent inhibition of viral protease activity by control compounds (black) or famotidine (green) when tested at various concentrations. The initial slopes of protein catalytic activity were converted from RFU/min to μmole fluorophore/min. Values are mean ± standard deviation of triplicates. The compounds tested in this experiment neither quenched fluorescence nor produced auto-fluorescence. Famotidine does not directly engage PL pro or 3CL pro of SARS-CoV-2. The function of many enzymes, such as proteases and kinases, can extend beyond their catalytic roles and includes a wide spectrum of non-catalytic activities such as allosteric regulation, scaffolding, protein-protein interactions, and protein-DNA interactions 22 . To rule out whether famotidine could bind away from the active site of the two viral proteases, and exert an effect through interference with non-proteolytic functions, we asked if famotidine is able to bind directly with either of the two SARS-CoV-2 proteases. For this, we employed two distinct biophysical techniques i.e. surface plasmon resonance (SPR) and differential scanning fluorimetry (DSF), that are routinely used to probe drug-protein engagement.

For our SPR studies, the biotinylated viral proteases were captured to a high density on sensor chips via neutravidin, permitting real-time detection of small-molecule binding to the target viral proteases. Engagement of the small-molecule compounds was recorded as an increase in dose-dependent response units (RU) during the assay. Experimental conditions including buffer composition and temperature were optimized using the control compounds prior to conducting the famotidine studies. The equilibrium dissociation constant (K d ) values were determined using both a kinetic analysis and fit to a binding isotherm of the dose response data (Fig. 2) . The observed K d values for the known 3CL pro and PL pro inhibitors (Supplementary Information Table S1 ) were consistent with the published IC 50 data 14, 21 indicating the robustness of our assay methodology. Under these www.nature.com/scientificreports/ optimized conditions, famotidine was not found to interact with either of the two viral proteases at concentration ranges of up to 100 uM.

To validate the results obtained from our SPR analysis, we employed an orthogonal DSF assay. DSF is a fluorescence-monitored thermal denaturing technique in which the melting temperature (T m ) of a protein is tracked via fluorescence as the sample temperature is incrementally raised in the presence of a hydrophobic dye. Drug binding to its target protein is known to stabilize (or destabilize) protein structure resulting in a variation of T m profiles in the absence or presence of a drug. DSF provides definitive confirmation of target engagement as the increase in thermal unfolding temperature (ΔT m ) is only achieved when the compounds bind to the folded state of the protein. The ΔT m is proportional to the K d of the interaction and concentration of the compound. We tested the ability of famotidine and the control inhibitors to alter the thermal stability profiles of PL pro and 3CL pro . An optimal signal profile was obtained with 7 μM PL pro or 3CL pro . Both proteins were tested separately in the presence of DMSO (-ve control), their respective control inhibitors, and famotidine at concentrations of 1, 2.5 and 5 mM. In agreement with the SPR data, the control inhibitors produced a quantitative increase in observed T m (Fig. 3) . While compound 6, the known PL pro inhibitor, stabilized PL pro by a T m shift of 6.6 °C (Fig. 3a) , and ML188, the 3CL pro inhibitor, produced a T m shift of 5.3 °C (Fig. 3b) , famotidine did not alter the T m of either of the two viral proteases. Taken together, the biophysical data decisively rules out the possibility of famotidine exerting its effect on PL pro or 3CL pro through interference with catalytic or non-catalytic protein functions as it is unable to bind with either of the two proteases.

famotidine does not inhibit SARS-CoV-2 proteases, we investigated the ability of famotidine to block virus replication in cell culture. For this, we infected Vero E6 cells, a commonly used cell model of SARS-CoV-2 infection derived from the African green monkey kidney. Infection efficiency was quantified through multiple, orthogonal readouts, including quantitative real-time PCR (qRT-PCR), plaque formation, and immunofluorescence. Remdesivir inhibited viral replication with an estimated half-maximum inhibitory concentration (IC 50 ) value of 3.3 μM, as determined by immunofluorescence (Fig. 4a) . In contrast, famotidine did not produce any measurable inhibition at concentrations of up to 200 μM at 72 h post infection. Similar results were obtained when viral replication was examined by infectious virion production using plaque formation assays or by quantifying viral RNA copy numbers in the cell culture medium using qRT-PCR (Supplementary Figures S1 and S2) .

To confirm these results in a more physiologically relevant cell model of SARS-CoV-2 infection, we assessed the antiviral activity of famotidine in human lung A549 cells. These cells were engineered to express essential SARS-CoV-2 entry factors, ACE2 and TMPRSS2 23 . The cells were infected with SARS-CoV-2 and cultured in the absence or presence of the control or test compounds. Virus replication (infection) efficiency was measured and reported as a function of compound concentration (Fig. 4) . While remdesivir strongly inhibited virus replication in a dose-dependent manner with an IC 50 value of 0.43 µM, famotidine had no measurable effect (Fig. 4b) . Our results are consistent with previously reported studies in which remdesivir exerted a greater antiviral effect in human lung A549 cells than in Vero E6 cells 24 . The fact that famotidine does not inhibit SARS-CoV-2 replication in the A549 cells which possess the serine protease TMPRSS2 also likely points to it having no effect on host proteases involved in viral entry.

In-parallel cytotoxicity assays, carried out in both Vero E6 and A549 cells, showed that famotidine was not toxic up to the highest tested concentrations of 200 μM (Fig. 4) . Remdesivir, on the other hand, exhibited dosedependent cytotoxicity at higher concentrations, well above its IC 50 . Together, these results show that famotidine www.nature.com/scientificreports/ does not inhibit SARS-CoV-2 replication in cultured cells and that its purported clinical benefit may be due to an alternative mechanism of action.

Two in silico studies have separately predicted the 3CL pro or PL pro of SARS-CoV-2 as potential molecular targets of famotidine 8, 9 , implying that famotidine associated improvement in COVID-19 patients may be due to a direct antiviral mechanism of action 6 . Despite recent advances in computational techniques, there are several challenges associated with the use of molecular docking to predict protein-ligand interactions accurately. Some of these challenges arise from the flexibility of the target protein, lack of prior knowledge of drug-binding sites, and protonation states of target amino acids 25 . While results obtained from molecular docking can serve as a basis for new hypotheses, experimental validation is needed. Our ligand-binding experiments using SPR and DSF did not support previous in silico predictions of direct binding between famotidine and SARS-CoV-2 proteases. We further used an array of experimental approaches to show that famotidine had no effect on SARS-CoV-2 protease function or generally on viral replication. It must be noted that since the clinical studies correlated putative clinical benefit with the use of higher doses of famotidine, we tested famotidine at significantly higher in-vitro concentrations than the peak plasma concentrations (0.5-2 µM) achieved in the blood of patients in both clinical studies 6, 7 . Our data strongly suggest that the probable clinical benefit of famotidine likely arises independently of an antiviral mechanism of action. COVID-19 complications are associated with a severe pro-inflammatory response in the lungs of infected patients 26 . The "cytokine storm" as a result of inflammation is a key pathognomonic feature of COVID-19 and the main contributor to respiratory failure and mortality 27 . Severe COVID-19 cases are characterized by pulmonary infiltration and extensive pulmonary edema, causing exudation of inflammatory cells in the alveolar space, resulting in extensive pulmonary consolidation leading to pneumonia and adult respiratory distress syndrome (ARDS) [28] [29] [30] [31] . The results of the two famotidine-related COVID-19 clinical reports, when taken together 6,7 , suggest that famotidine likely helps with mitigating moderate to severe respiratory symptoms ranging from shortness of breath to intubation. Our data does not rule out the possibility that famotidine related improvements in COVID-19 patients are through an anti-inflammatory action. For example, the development of the cytokine storm in COVID-19 patients is characterized by elevation of pro-inflammatory type I cytokines, which are secreted from a variety of cells such as polymorphonuclear cells, natural killer cells, and endothelial cells, etc 27 . www.nature.com/scientificreports/ It is therefore conceivable that famotidine-related benefit in managing respiratory symptoms may be due to an anti-inflammatory mechanism of action. It is noteworthy that H2R, the established molecular target of famotidine, is involved in the activation of several mediators of the adaptive immune response, such as Th1 lymphocytes, which are implicated in proinflammatory cytokine production 32 . Histamine, the H2R ligand, also regulates bronchoconstriction, airway inflammation, and vasodilation 32 . Mast cells are a major source of histamine and their activation has been reported following viral infections of the respiratory tract [33] [34] [35] . Therefore, Mast cells may represent an underappreciated source of pro-inflammatory cytokine release in COVID-19 patients 33 . A better understanding of the role of the H2R pathway in COVID-19 will help elucidate the molecular details of how famotidine reduces the disease severity.

Our in-vitro study redirects the mechanism behind the potential beneficial effect of famotidine, away from an antiviral effect to likely an anti-inflammatory action in COVID-19 patients. Given that there is an ongoing randomized clinical trial (NCT04370262), our results may assist the investigators in reshaping their interventional study to include inflammation-related outcomes. Also, it should be noted that while famotidine is one of the relatively safer drugs, its use is not without risk [36] [37] [38] , especially in elderly patients (a high-risk population for COVID- 19) , in which famotidine use has been associated with CNS complications 39 . Provided the ongoing clinical trial yields promising results, further investigation of famotidine and its safety profile in different age brackets will be needed before the drug can be used, most likely as part of a combination therapy, for COVID-19 disease management.

Compounds. Cloning, expression, and protein purification. The complete sequences encoding 3CL pro and residues 746-1060 of PL pro (Wuhan-Hu-1 isolate, GenBank accession NC_045512) were cloned into a charge modified SUMO fusion expression vector, generated in-house. The fusion protein was expressed for 24 h in Rosetta-2 (DE3) pLysS at 18 °C in ZYP-5052 autoinducing media. Harvested cells were resuspended in 50 mM Hepes pH 7.5, containing 150 mM NaCl and lysed by sonication. The clarified supernatant was loaded onto a HiTrap HP SP column (Cytiva, Massachusetts, USA; cat no. 17115201) and the target fusion protein was captured in a cationexchange chromatography step and eluted using a NaCl gradient. SUMO hydrolase was added to the pooled fractions to liberate the target protein and the sample dialyzed against 20 mM Tris, 10% v/v glycerol, 5 mM DTT pH 7.0 overnight at 4 °C. The protein was reloaded on the HiTrap HP SP column to remove the SUMO protein and hydrolase in a subtractive step. The flow-through, containing 3CL pro or PL pro was further purified by anion exchange chromatography using a HiTrap HP Q column (Cytiva; cat. no. 17115401) employing a NaCl gradient to elute the protein. Pooled fractions were further purified by size exclusion chromatography in 20 mM Tris pH 7.4, 150 mM NaCl and 5 mM DTT. The final protein was concentrated to 4 mg/mL for PL pro and 5 mg/mL for 3CL pro and flash frozen in aliquots.

In-vitro viral enzyme assays. PL pro proteolytic activity assay using ubiquitin-AMC. PL pro activity was measured in a 384 well plate format (Corning #3574) in a kinetic assay using the fluorogenic substrate Ubiquitin-AMC (Boston Biochem, Inc. Massachusetts, USA; cat. No. U-550) with excitation and emission wavelengths of Ex355nm/Em:460 nm. The protocol followed previously reported conditions with minor modifications 13,16 . Fluorescence was monitored at 25 °C, every 5 min for 50 min in a Victor X5 (Perkin Elmer) multimode plate reader. Optimal enzyme and substrate concentrations were found to be 550 nM PL pro titrating the substrate in the range of 0.2 -3 μM. The assay buffer (20 μL) contained 25 mM HEPES pH 7.5, 100 mM NaCl, 0.1 mg/ml BSA, and 550 nM PL pro . The test inhibitor, famotidine and the PL pro control inhibitor (compound 6) were both titrated in the concentration range of 0.01 μM -200 μM. Compounds were incubated with the enzyme in the plate for 30 min at 25 °C before the reaction was started by the addition of 1 μM Ub-AMC. All samples were run in triplicates and their initial slopes were converted from relative fluorescence units (RFU)/ min to μmol AMC/ min using an AMC standard curve and plotted against compound concentrations tested.

3CL pro proteolytic activity assay. 3CL pro activity was assayed in a 384 well plate using the 3CL pro FRET substrate (AnaSpec, Inc. California, USA; cat. no. AS-65599) with excitation and emission wavelengths of Ex: 490 nm/ Em: 535 nm. A previously reported protocol was used with some modifications 12, 17 . The kinetics of fluorescence change were monitored every minute for 25 min. Optimal concentrations for 3CL pro and substrate were 150 nM and 600 nM respectively. A previously reported 3CL pro inhibitor 14 www.nature.com/scientificreports/ parameters logistic (4PL) equations (y = min + (max-min)/(1 + (x/EC50)^Hillslope)) respectively, using Graph-Pad Prism 8. To infect cells, the compound-containing medium was removed, and the cells were incubated with the virus for 1 h at 37ºC. The virus inoculum was then removed, and the cell monolayer was rinsed twice with 1X PBS. The compounds were added back followed by incubation for 72 h, after which the cell culture medium was harvested for quantitative real-time PCR (qRT-PCR) and plaque assays, while the cells were fixed with 4% paraformaldehyde for immunofluorescence microscopy.

Virus RNA extraction and quantitative real-time PCR (qRT-PCR). RNA was isolated from the cell culture supernatant of SARS-CoV-2-infected cells using the Quick-RNA Viral Kit (Zymo, California, USA cat no. R1035) according to the manufacturer's instructions. Viral RNA was quantified using single-step RT-quantitative realtime PCR using the qScript One-Step RT-qPCR Kit (Quantabio, Massachusetts, USA; cat no. 95058) with primers and Taqman probes targeting the SARS-CoV-2 E gene as previously described 42 www.nature.com/scientificreports/ USA). At least 7-10 microscopic fields were imaged per well using a 10X objective lens, the number of cells positive for the SARS-CoV-2 N protein and the nuclear DAPI stain, were counted. For each image, the percentage of DAPI-positive cells expressing the viral N protein were calculated, and the mean ± SD of multiple images for each condition was plotted.

Cytotoxicity/cell viability assay. The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Wisconsin, USA; cat no. G7570) was used to determine the cytotoxic effects of the compounds. Briefly, the cells were incubated with five-fold serial dilutions of famotidine or remdesivir for 72 h, after which the CellTiter-Glo Reagent was added to each well in a volume equal to the volume of the culture medium. The contents were mixed by shaking the plate on an orbital shaker for 2 min, followed by a 10 min incubation at room temperature. Luminescence was recorded using a Varioskan LUX multimode plate reader (ThermoFisher Scientific, Massachusetts, USA).

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 2 November 2020; Accepted: 1 February 2021

Coronavirus puts drug repurposing on the fast track

Remdesivir for the treatment of Covid-19 -preliminary report

A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

Histamine H2-receptor antagonists

Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

15 drugs being tested to treat COVID-19 and how they would work

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity

Ligand-induced dimerization of middle east respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals

Catalytic function and substrate specificity of the papainlike protease domain of nsp3 from the Middle East respiratory syndrome coronavirus

Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

Structural basis for the non-catalytic functions of protein kinases

Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Exponential consensus ranking improves the outcome in docking and receptor ensemble docking

The trinity of COVID-19: immunity, inflammation and intervention

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Covid-19 in critically Ill patients in the seattle region-case series

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets

Mast cell responses to viruses and pathogen products

Influenza infection in mice induces accumulation of lung mast cells through the recruitment and maturation of mast cell progenitors

Mast cell-induced lung injury in mice infected with H5N1 influenza virus

Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements

Famotidine-induced retinopathy

Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy

Central nervous system reactions to histamine-2 receptor blockers

SimpleDSFviewer: a tool to analyze and view differential scanning fluorimetry data for characterizing protein thermal stability and interactions

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

This work was partially supported by the Evergrande MassCPR award to MS and DYC.

The authors declare no competing interests.

The online version contains supplementary material available at https ://doi. org/10.1038/s4159 8-021-84782 -w.Correspondence and requests for materials should be addressed to M.S. or A.H.M.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.